Gapping up
In reaction to strong earnings/guidance: BBRY +8.3%, DRI +6.7%
M&A news: EXXI +3.6% (confirmed sale of its Grand Isle Gathering System to CorEnergy Infrastructure Trust (CORR) for $245 mln), SYT +0.5% (Chairman reaffirms stance regarding Monsanta (MON) takeover offer in video interview; states MON trying to buy the co on the cheap)
Select EU related names showing cont strength: ALV +2.4%, SHPG +1.9%, SNY +1.5%, UN +1.2%, ALU +1%
Other news: GDOT +30.6% (announced 5-year agreement with Walmart (WMT) and $150 mln stock buyback), PHMD +19% (announces the sale of its worldwide XTRAC and VTRAC psoriasis and vitiligo treatment businesses to MELA Sciences (MELA) for $42.5 mln in cash (MELA) shares halted) ), AMRN +15.6% (will present new in vitro eicosapentaenoic acid study data; found that EPA reduced cholesterol crystalline domain levels in cholesterol-enriched model membranes by 65%will present new in vitro eicosapentaenoic acid study data; found that EPA reduced cholesterol crystalline domain levels in cholesterol-enriched model membranes by 65%), BIND +7.5% (FDA authorizes clinical trial with AstraZeneca's (AZN) Aurora B kinase inhibitor), WAC +4.3% (Baker Street Capital disclosed 22.3% active stake in 13D filing), SGYP +4% (initiates a second Phase 3 clinical trial of Plecanatide), KEG +3.5% (named Robert Drummond President and COO)), NBG +3.1% (optimism of Greece deal in coming days), AMBA +3% (modest strength following yday's sell off), QURE +2.3% (Bristol-Myers Squibb discloses 4.9% passive stake in 13G filing; stake to rise to 9.9% upon future purchases required under agreement between the companies), MDR +2.2% (awarded a lump sum contract by LLOG Exploration Offshore, for services in the Gulf of Mexico), APPY +1.2% (to host an investor conference call to provide an update on regulatory and business matters, on Wednesday, June 24, 2015, at 4:30 p.m. ET), KRFT +1% (declares special cash dividend of $16.50 per share, conditioned upon closing of proposed merger with Heinz ), HZNP +1% (USPTO issues an additional notice of allowance with claims covering Ravicti oral liquid), RDUS +0.9% (favorable commentary on Monday's Mad Money), NSPH +0.8% (announced the presentation of new studies highlighting antibiotic resistance detection with its verigene blood culture tests), VIMC +0.8% (receives $22 mln contract for the provision of SVAC-compliant video surveillance cameras and system to Jincheng Municipal Government in Shanxi Province)
Analyst comments: CASI +6.6% (initiated with a Buy at H.C. Wainwright; tgt $2.50), LPCN +3.1% (initiated with a Buy at Canaccord Genuity; $15 tgt), DEO +2.3% (upgraded to Buy from Neutral at Nomura), T +1.6% (upgraded to Overweight from Equal Weight at Barclays; upgraded to Buy from Neutral at UBS), VOD +1.5% (upgraded to Buy from Neutral at Nomura),YELP +1.4% (initiated with a Buy at Topeka Capital Markets ), PRGO +1.2% (initiated with an Outperform at BMO Capital), CI +0.9% (target raised to $175 from $160 at Leerink Partners), JBLU +0.9% (upgraded to Equal-Weight from Underweight at Morgan Stanley), DAL +0.9% (assumed with a Overweight at Morgan Stanley), IHG +0.9% (upgraded to Outperform at Credit Suisse), SNN +0.6% (upgraded to Buy from Neutral at UBS), GG +0.6% (upgraded to Action List Buy at TD Securities; $29 tgt
)
In reaction to strong earnings/guidance: BBRY +8.3%, DRI +6.7%
M&A news: EXXI +3.6% (confirmed sale of its Grand Isle Gathering System to CorEnergy Infrastructure Trust (CORR) for $245 mln), SYT +0.5% (Chairman reaffirms stance regarding Monsanta (MON) takeover offer in video interview; states MON trying to buy the co on the cheap)
Select EU related names showing cont strength: ALV +2.4%, SHPG +1.9%, SNY +1.5%, UN +1.2%, ALU +1%
Other news: GDOT +30.6% (announced 5-year agreement with Walmart (WMT) and $150 mln stock buyback), PHMD +19% (announces the sale of its worldwide XTRAC and VTRAC psoriasis and vitiligo treatment businesses to MELA Sciences (MELA) for $42.5 mln in cash (MELA) shares halted) ), AMRN +15.6% (will present new in vitro eicosapentaenoic acid study data; found that EPA reduced cholesterol crystalline domain levels in cholesterol-enriched model membranes by 65%will present new in vitro eicosapentaenoic acid study data; found that EPA reduced cholesterol crystalline domain levels in cholesterol-enriched model membranes by 65%), BIND +7.5% (FDA authorizes clinical trial with AstraZeneca's (AZN) Aurora B kinase inhibitor), WAC +4.3% (Baker Street Capital disclosed 22.3% active stake in 13D filing), SGYP +4% (initiates a second Phase 3 clinical trial of Plecanatide), KEG +3.5% (named Robert Drummond President and COO)), NBG +3.1% (optimism of Greece deal in coming days), AMBA +3% (modest strength following yday's sell off), QURE +2.3% (Bristol-Myers Squibb discloses 4.9% passive stake in 13G filing; stake to rise to 9.9% upon future purchases required under agreement between the companies), MDR +2.2% (awarded a lump sum contract by LLOG Exploration Offshore, for services in the Gulf of Mexico), APPY +1.2% (to host an investor conference call to provide an update on regulatory and business matters, on Wednesday, June 24, 2015, at 4:30 p.m. ET), KRFT +1% (declares special cash dividend of $16.50 per share, conditioned upon closing of proposed merger with Heinz ), HZNP +1% (USPTO issues an additional notice of allowance with claims covering Ravicti oral liquid), RDUS +0.9% (favorable commentary on Monday's Mad Money), NSPH +0.8% (announced the presentation of new studies highlighting antibiotic resistance detection with its verigene blood culture tests), VIMC +0.8% (receives $22 mln contract for the provision of SVAC-compliant video surveillance cameras and system to Jincheng Municipal Government in Shanxi Province)
Analyst comments: CASI +6.6% (initiated with a Buy at H.C. Wainwright; tgt $2.50), LPCN +3.1% (initiated with a Buy at Canaccord Genuity; $15 tgt), DEO +2.3% (upgraded to Buy from Neutral at Nomura), T +1.6% (upgraded to Overweight from Equal Weight at Barclays; upgraded to Buy from Neutral at UBS), VOD +1.5% (upgraded to Buy from Neutral at Nomura),YELP +1.4% (initiated with a Buy at Topeka Capital Markets ), PRGO +1.2% (initiated with an Outperform at BMO Capital), CI +0.9% (target raised to $175 from $160 at Leerink Partners), JBLU +0.9% (upgraded to Equal-Weight from Underweight at Morgan Stanley), DAL +0.9% (assumed with a Overweight at Morgan Stanley), IHG +0.9% (upgraded to Outperform at Credit Suisse), SNN +0.6% (upgraded to Buy from Neutral at UBS), GG +0.6% (upgraded to Action List Buy at TD Securities; $29 tgt
)